Long-Term ERLEADA ® (apalutamide) Patient-Reported Outcomes Data in Metastatic Castration-Sensitive Prostate Cancer Demonstrate Maintenance of Health-Related Quality of Life for Patients

May 26, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced patient-reported outcomes (PRO) data from the pre-specified final analysis of the Phase 3 TITAN study in patients with metastatic castration-sensitive prostate cancer (mCSPC). The TITAN study previously demonstrated statistically significant improvement in overall survival (OS) after a median follow-up of 44 months in patients receiving ERLEADA® plus androgen deprivation therapy (ADT).1 The new PRO data showed that the addition of ERLEADA® to ADT maintained patients’ health-related quality of life (HRQoL) and did not worsen side effect burden, consistent with ADT alone.[1] These data are being presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8 (Abstract #5068).“Concern about side effects and their resulting burden on quality of life can be a barrier for patients when considering treatment options,” said Neeraj Agarwal, M.D., of the University of Utah Huntsman Cancer Institute, and the lead study investigator for TITAN.* “The significant long-term overall survival benefit we’ve seen demonstrated with ERLEADA, with no impact on quality of life as reported by patients, underscores the important role of this therapy in the treatment of advanced prostate cancer.” No significant differences in quality of life were observed between patients who received ERLEADA® plus ADT and patients...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news

Related Links:

A lot of questions about the Pfizer/BioNTech booster shots are circulating after decisions from the FDA and the CDC and recommendations from two vaccine advisory committees.Medscape Medical News
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Infectious Diseases News Source Type: news
No abstract available
Source: Topics in Pain Management - Category: Anesthesiology Tags: CONTINUING EDUCATION ACTIVITY Source Type: research
No abstract available
Source: Topics in Pain Management - Category: Anesthesiology Tags: ARTICLE Source Type: research
No abstract available
Source: Topics in Pain Management - Category: Anesthesiology Tags: ARTICLE Source Type: research
No abstract available
Source: Topics in Pain Management - Category: Anesthesiology Tags: ARTICLE Source Type: research
No abstract available
Source: Topics in Pain Management - Category: Anesthesiology Tags: CME/NCPD Quiz Source Type: research
No abstract available
Source: Topics in Pain Management - Category: Anesthesiology Tags: NEWS IN BRIEF Source Type: research
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A c...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
RARITAN, N.J., April 19, 2021 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that regulatory submissions based on the Phase 3 ACIS study, which evaluated the combination of ERLEADA® (apalutamide) and ZYTIGA® (abiraterone acetate) plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC), will not be pursued. As presented at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cancers Symposium in February 2021, the ACIS study met its primary endpoint of radiographic progression-free survival (rPFS); how...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today results from the final analysis of the Phase 3 TITAN study, which demonstrated the continued statistically significant benefit of the addition of ERLEADA® (apalutamide) to androgen deprivation therapy (ADT) in overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC), regardless of extent of disease, when compared to placebo plus ADT.[1] Results will be featured in an oral presentation at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cancer...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
More News: Allergy & Immunology | Anemia | Brain | Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Cancer Vaccines | Cardiology | Cardiovascular | Chemistry | Chemotherapy | Chronic Pain | Clinical Trials | Corticosteroid Therapy | Diabetes | Docetaxel | Endocrinology | Epilepsy | Food and Drug Administration (FDA) | Health Management | Heart | Heart Disease | Hematology | Hormonal Therapy | Hormones | Hypertension | Hypothyroidism | Infectious Diseases | Laboratory Medicine | Learning | Legislation | Men | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Radiation Therapy | Neoadjuvant Therapy | Neurology | Neuroscience | Oral Cancer | Organic | Orthopaedics | Pain | Pain Management | Pharmaceuticals | Pregnancy | Pregnancy and Breast Cancer | Profits and Losses | Prostate Cancer | Pulmonary Hypertension | Radiation Therapy | Radiography | Science | Statistics | Study | Taxotere | Thyroid | Thyroid Cancer | Toxicology | Universities & Medical Training | Urology & Nephrology | Vaccines